Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 417, doi. 10.1038/gt.2012.55
- By:
- Publication type:
- Article
Works matching IS 09697128 AND DT 2013 AND VI 20 AND IP 4
Results: 14
1
2
Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 435, doi. 10.1038/gt.2012.54
- By:
- Publication type:
- Article
3
BMP-6 is more efficient in bone formation than BMP-2 when overexpressed in mesenchymal stem cells.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 370, doi. 10.1038/gt.2012.45
- By:
- Publication type:
- Article
4
Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 460, doi. 10.1038/gt.2012.67
- By:
- Publication type:
- Article
5
High-affinity PEGylated polyacridine peptide polyplexes mediate potent in vivo gene expression.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 407, doi. 10.1038/gt.2012.47
- By:
- Publication type:
- Article
6
Matrix metalloproteinase-inspired suicidal treatments of diabetic ulcers with siRNA-decorated nanofibrous meshes.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 378, doi. 10.1038/gt.2012.49
- By:
- Publication type:
- Article
7
Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 425, doi. 10.1038/gt.2012.53
- By:
- Publication type:
- Article
8
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 450, doi. 10.1038/gt.2012.101
- By:
- Publication type:
- Article
9
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 386, doi. 10.1038/gt.2012.48
- By:
- Publication type:
- Article
10
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL<sup>S447X</sup>) gene therapy for lipoprotein lipase deficiency: an open-label trial.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 361, doi. 10.1038/gt.2012.43
- By:
- Publication type:
- Article
11
Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 444, doi. 10.1038/gt.2012.62
- By:
- Publication type:
- Article
12
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 465, doi. 10.1038/gt.2013.11
- By:
- Publication type:
- Article
13
Bioprocess development for canine adenovirus type 2 vectors.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 353, doi. 10.1038/gt.2012.52
- By:
- Publication type:
- Article
14
SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery.
- Published in:
- Gene Therapy, 2013, v. 20, n. 4, p. 396, doi. 10.1038/gt.2012.50
- By:
- Publication type:
- Article